The CYP125 Polyclonal Antibody (PACO34598) is a valuable tool for researchers studying CYP125, a cytochrome P450 enzyme involved in lipid metabolism in mycobacteria. This antibody, generated in rabbits, is highly specific for CYP125 and has been validated for use in various applications, including Western blotting.CYP125 plays a crucial role in the degradation of cholesterol and other sterols, making it a potential target for drug development against mycobacterial infections such as tuberculosis.
By targeting CYP125, researchers can gain insights into the mechanisms of mycobacterial lipid metabolism and potentially identify new therapeutic strategies.The CYP125 Polyclonal Antibody is an essential tool for research in microbiology, tuberculosis drug discovery, and lipid metabolism. Its high specificity and reliability make it a valuable asset for studies aiming to understand the role of CYP125 in mycobacterial pathogenesis and identify novel drug targets for combating these infections.
Antibody Name:
cyp125 Antibody (PACO34598)
Antibody SKU:
PACO34598
Size:
50ug
Host Species:
Rabbit
Tested Applications:
ELISA
Recommended Dilutions:
Species Reactivity:
Mycobacterium tuberculosis
Immunogen:
Recombinant Mycobacterium tuberculosis Steroid C26-monooxygenase protein (1-433AA)
Catalyzes the C-27 hydroxylation of cholest-4-en-3-one and cholesterol and subsequently oxidizes the alcohol of the former to the cholest-4-en-3-one-27-oic acid, via the aldehyde intermediate. Not required to incorporate the cholesterol side-chain carbon atoms into cellular lipids.
Involved in the utilization of cholesterol as the sole carbon and energy source by degrading the side chain during infection (PubMed:20843794, PubMed:20545858). Primarily catalyzes the sequential oxidation of the terminal methyl of cholest-4-en-3-one into (25S)-26-hydroxycholest-4-en-3-one (alcohol), (25S)-26-oxocholest-4-en-3-one (aldehyde), to finally yield the carboxylic acid (25S)-3-oxocholest-4-en-26-oate (PubMed:19846551, PubMed:20843794, PubMed:20545858). Also able to sequentially oxidize cholesterol itself, not only cholest-4-en-3-one (PubMed:19846551, PubMed:20843794, PubMed:20545858).
